Entera Bio Ltd. (ENTX)
Fuera de horario:
Entera Bio Ltd.
Kiryat Hadassah Minrav Building
Fifth Floor
Jerusalem 9112002
Israel
972 2 532 7151
https://www.enterabio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 17
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Miranda J. Toledano M.B.A. | CEO & Director | 418k | N/D | 1977 |
| Ms. Dana Yaacov-Garbeli CPA | Chief Financial Officer | 193k | N/D | 1983 |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer | 296k | N/D | 1978 |
Descripción
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Gestión corporativa
La calificación ISS Governance QuickScore de Entera Bio Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
